Last reviewed · How we verify
NCT04862117
Long Term Extension of Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)
NA trial testing SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System in Rheumatoid Arthritis in 14 participants. Participants enrolled and being followed up; not accepting new ones.
8 December 2026
Quick facts
| Lead sponsor | SetPoint Medical Corporation |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 14 |
| Start date | 28 July 2018 |
| Primary completion | 8 December 2026 |
| Estimated completion | 8 December 2026 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System
Conditions studied
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
Sponsor
SetPoint Medical Corporation — full company profile →
Who can join
Adults 22 to 75, any sex, with Rheumatoid Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Long-term extension of a multi-site, first-in-human study to assess safety and efficacy of an active implantable Vagus Nerve Stimulation (VNS) device in adult patients with active moderate-to-severe rheumatoid arthritis who have had an incomplete response or intolerability to at least two biologic and/or targeted synthetic DMARDs having at least two different mechanisms of action
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neuroimmune Modulation for Drug-Refractory Rheumatoid Arthritis: Long-Term Safety and Efficacy in Patients Enrolled in a Pilot Vagus Nerve Stimulation Study.
Gaylis NB, Sikes D, Kivitz A, Horowitz DL, et al · · 2025 · cited 2× · PMID 41071520 · DOI 10.1007/s40744-025-00798-y -
Macrophages as central mediators of sympathetic neuro-immune interplay in autoimmunity.
Muntjewerff EM, Josyula VS, Lehmair F, Christoffersson G. · · 2025 · PMID 41476959 · DOI 10.3389/fimmu.2025.1654382
Verify or expand the search:
- PubMed search for NCT04862117
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System
Trials testing the same drug.
- NCT03437473 — Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA) · NA · completed
Other recruiting trials for Rheumatoid Arthritis
Currently open trials in the same condition.
- NCT07433335 — A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07171983 — A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis · Phase 1 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07363590 — A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) · Phase 1 · recruiting
Other SetPoint Medical Corporation trials
Trials by the same sponsor.
- NCT07489326 — The SetPoint System Safety & Performance Post-Approval Study · not yet recruiting
- NCT06796504 — The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study · NA · recruiting
- NCT03437473 — Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04862117 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SetPoint Medical Corporation
- Last refreshed: 13 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04862117.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing